Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Opdivo in bladder cancer after BCG immunotherapy
NCT03106610Phase 1Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2017
- Primary completion
- May 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of nivolumab in bladder cancer, sponsored by University of Texas MD Anderson Cancer Center. Started Jul 2017; status: terminated.
02
Drugs
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT03106610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03106610.